344 related articles for article (PubMed ID: 33724133)
1. Development of thermostable vaccine adjuvants.
Qi Y; Fox CB
Expert Rev Vaccines; 2021 May; 20(5):497-517. PubMed ID: 33724133
[TBL] [Abstract][Full Text] [Related]
2. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives.
Zeng Y; Zou F; Xia N; Li S
Expert Rev Vaccines; 2023; 22(1):681-695. PubMed ID: 37496496
[TBL] [Abstract][Full Text] [Related]
3. Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.
Kramer RM; Archer MC; Orr MT; Dubois Cauwelaert N; Beebe EA; Huang PD; Dowling QM; Schwartz AM; Fedor DM; Vedvick TS; Fox CB
Int J Nanomedicine; 2018; 13():3689-3711. PubMed ID: 29983563
[TBL] [Abstract][Full Text] [Related]
4. Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method.
Chen D; Kapre S; Goel A; Suresh K; Beri S; Hickling J; Jensen J; Lal M; Preaud JM; Laforce M; Kristensen D
Vaccine; 2010 Jul; 28(31):5093-9. PubMed ID: 20478345
[TBL] [Abstract][Full Text] [Related]
5. Carbohydrate-based vaccine adjuvants - discovery and development.
Hu J; Qiu L; Wang X; Zou X; Lu M; Yin J
Expert Opin Drug Discov; 2015 Oct; 10(10):1133-44. PubMed ID: 26372693
[TBL] [Abstract][Full Text] [Related]
6. Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.
Ou B; Yang Y; Lv H; Lin X; Zhang M
BioDrugs; 2023 Mar; 37(2):143-180. PubMed ID: 36607488
[TBL] [Abstract][Full Text] [Related]
7. The next generation of HCV vaccines: a focus on novel adjuvant development.
Kardani K; Sadat SM; Kardani M; Bolhassani A
Expert Rev Vaccines; 2021 Jul; 20(7):839-855. PubMed ID: 34114513
[TBL] [Abstract][Full Text] [Related]
8. Immunostimulant plant proteins: Potential candidates as vaccine adjuvants.
Nazeam JA; Singab ANB
Phytother Res; 2022 Dec; 36(12):4345-4360. PubMed ID: 36128599
[TBL] [Abstract][Full Text] [Related]
9. Liposomal adjuvants for human vaccines.
Alving CR; Beck Z; Matyas GR; Rao M
Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300
[TBL] [Abstract][Full Text] [Related]
10. Adjuvants for vaccines to drugs of abuse and addiction.
Alving CR; Matyas GR; Torres O; Jalah R; Beck Z
Vaccine; 2014 Sep; 32(42):5382-9. PubMed ID: 25111169
[TBL] [Abstract][Full Text] [Related]
11. Micronanoparticled risedronate exhibits potent vaccine adjuvant effects.
Nie M; Wu S; Chen Y; Wu Y; Chen R; Liu Y; Yue M; Jiang Y; Qiu D; Yang M; Wang Z; Gao J; Xiong H; Qi R; He J; Zhang J; Zhang L; Wang Y; Fang M; Que Y; Yao Y; Li S; Zhang J; Zhao Q; Yuan Q; Zhang T; Xia N
J Control Release; 2024 Jan; 365():369-383. PubMed ID: 37972764
[TBL] [Abstract][Full Text] [Related]
12. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
Nordly P; Madsen HB; Nielsen HM; Foged C
Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
[TBL] [Abstract][Full Text] [Related]
13. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
Chauhan N; Tiwari S; Iype T; Jain U
Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554
[TBL] [Abstract][Full Text] [Related]
14. Stability of lyophilized and spray dried vaccine formulations.
Preston KB; Randolph TW
Adv Drug Deliv Rev; 2021 Apr; 171():50-61. PubMed ID: 33484735
[TBL] [Abstract][Full Text] [Related]
15. Development of nano-carriers for
Askarizadeh A; Badiee A; Khamesipour A
Expert Opin Drug Deliv; 2020 Feb; 17(2):167-187. PubMed ID: 31914821
[No Abstract] [Full Text] [Related]
16. SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways.
Mekonnen D; Mengist HM; Jin T
Expert Rev Vaccines; 2022 Jan; 21(1):69-81. PubMed ID: 34633259
[TBL] [Abstract][Full Text] [Related]
17. Adjuvants for human vaccines--current status, problems and future prospects.
Gupta RK; Siber GR
Vaccine; 1995 Oct; 13(14):1263-76. PubMed ID: 8585280
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant formulations for virus-like particle (VLP) based vaccines.
Cimica V; Galarza JM
Clin Immunol; 2017 Oct; 183():99-108. PubMed ID: 28780375
[TBL] [Abstract][Full Text] [Related]
19. Lyophilization of Adjuvanted Vaccines: Methods for Formulation of a Thermostable Freeze-Dried Product.
Chan MY; Dutill TS; Kramer RM
Methods Mol Biol; 2017; 1494():215-226. PubMed ID: 27718196
[TBL] [Abstract][Full Text] [Related]
20. Rational design of polymer-based particulate vaccine adjuvants.
Huete-Carrasco J; Lynch RI; Ward RW; Lavelle EC
Eur J Immunol; 2024 Feb; 54(2):e2350512. PubMed ID: 37994660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
